Tricuspid regurgitation and heart failure: the fate of treated vs. untreated cohort in the percutaneous era.

ABSTRACT:

Aims

Tricuspid regurgitation (TR) is associated with heart failure (HF) and reduced survival. Within a short-time period, transcatheter tricuspid valve repair or replacement (TTVR/TTVr) for TR has evolved from innovation to clinical reality. The present study's aim is to provide 1-year results between TR patients treated with TTVR and TTVr compared with untreated patients, in terms of cardiac survival, rehospitalization, right-side HF symptom development, and New York Heart Association (NYHA) improvement.

Methods and results

Seventy-seven patients (pts) have been prospectively inserted into a dedicated database from January 2020 till January 2023. Twenty-six patients (33.8%) have been treated with TTVR/r [treated group (TG)], and 51 pts (66.2%) have been left untreated with

SUBMITTER: Zancanaro E 

PROVIDER: S-EPMC11367954 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature